{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 55,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "Waterfall plot shows tumor shrinkage; includes key clinical metrics (ORR, mPFS) and safety/future trial status.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/47",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Waterfall plot of best change from baseline in tumor size",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70630b33-8df4-4525-848d-8f211d08e654",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.63,
        "y": 0.25
      },
      "kind": "list",
      "text": "Meaningful ORR, durable responses and encouraging PFS in PD-L1 TC <1%; volrustomig + CTx regimen had manageable safety profile; Ongoing Phase III eVOLVE-Lung02 in PD-L1 <50% NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68c8e223-7a10-4aa0-864c-ce2a3d486e51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Spigel DR et al. Abstract OA11.04 presented at the 2024 World Conference on Lung Cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d96c1b20-b2a0-4982-bc75-0b648cb3239c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "volrustomig + CTx – promising activity, particularly in PD-L1<1% population, a group with high unmet need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2a7f483-9bf8-4c6a-a5dd-5cb27114dfcb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "9f5ec4e5-dcbd-48f7-9d39-65e67987f2fb",
      "evidence": "chart/waterfall: Waterfall plot of best change from baseline in tumor size",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}